Skip to main content
Premium Trial:

Request an Annual Quote

OpGen Inks $17M Financing Deal

NEW YORK (GenomeWeb News) – OpGen has completed an agreement with new and existing investors to provide the firm with up to $17 million in a Series C financing.

The Gaithersburg, Md.-based firm said that the proceeds will be used to accelerate commercialization of its Argus Whole Genome Mapping System and Genome-Builder tool suite for large genome sequencing assembly and data analysis. OpGen also has plans to introduce a new application for whole human chromosome mapping that can be combined with next-generation sequencing techniques to improve the accuracy of human genome sequencing.

According to a filing with the US Securities and Exchange Commission last month, OpGen had raised $3.5 million, which a spokesman confirmed was part of the Series C round.

New investors in the round included Harris & Harris Group and Cross Creek Capital, an affiliate of Wasatch Advisors, as well as previous investors Highland Capital Partners, Versant Ventures, jVen Capital, and CHL Medical Partners.

In a separate statement, Harris & Harris disclosed that its investment in the round was $815,000. It also noted that its Managing Director, Misti Ushio, will join OpGen's board of directors.

"For the past several years, Harris & Harris Group has been looking for the next transformative technology that goes beyond high-throughput sequencing," Ushio said in a statement. "We are excited to have the opportunity to invest in OpGen, which has launched its Whole Genome Mapping system enabling rapid analysis of structural variation."

The Scan

Panel Votes for COVID-19 Pill

A US Food and Drug Administration panel has voted to support the emergency use authorization of an antiviral pill for COVID-19 from Merck and Ridgeback Biotherapeutics, CNN says.

But Not Harm

New Scientist reports that UK bioethicists say that though gene editing may improve food production, it should not harm livestock welfare.

Effectiveness Drop Anticipated

Moderna's Stéphane Bancel predicts that that current SARS-CoV-2 vaccines may be less effective against the Omicron variant, the Financial Times reports.

Cell Studies of Human Chromatin Accessibility, SARS-CoV-2 Variants, Cell Signaling Networks

In Cell this week: chromatin accessibility maps of adult human tissues, modeling to track SARS-CoV-2 variants of concern, and more.